ArticleCancer reports (Hoboken, N.J.)2026
Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case Report and Literature Review.International journal of molecular sciences · 2026Review
- Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab is approved for treating patients with advanced solid tumors exhibiting high tumor mutation burden (TMB), including pancreatic cancer. However, owing to the rarity of TMB-high pancreatic cancer, its genetic and clinical characteristics, alongside the therapeutic effectiveness of pembrolizumab, remain unclear.
aimsTo investigate the characteristics and assess the effectiveness of pembrolizumab in this patient population. METHODS AND
resultsWe retrospectively reviewed data of 293 patients with unresectable or recurrent pancreatic cancer who underwent comprehensive genomic profiling at our hospital between December 2019 and April 2023. TMB-high was observed in 13 cases (4.4%), including four patients with microsatellite instability-high (MSI-H) (1.4%). Two patients exhibited germline BRCA2 mutations: one with adenocarcinoma and the other with acinar cell carcinoma. Germline mutations in MLH1 and MSH6 were each identified in one case, both exhibiting MSI-H plus TMB-high. The frequency of pathogenic mutations in KRAS, TP53, CDKN2A, and SMAD4 was notably high. KRAS mutations were detected in 12 of the 13 patients (92.3%). Pembrolizumab was administered to six patients, yielding an objective response rate of 33.3% and a disease control rate of 66.7%. Among the three patients with MSI-H plus TMB-high, two achieved partial response, and the median progression-free survival for all three patients was 227 days. Among the three microsatellite stable (MSS) plus TMB-high cases, two exhibited stable disease, and the median progression-free survival for all three patients was 90 days.
conclusionThe frequency of TMB-high was 4.4%, which is slightly higher than that previously reported. Pembrolizumab demonstrated greater efficacy in patients with MSI-H plus TMB-high while also exhibiting some efficacy in patients with MSS plus TMB-high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.